MET expression during prostate cancer progression

Esther I. Verhoef; Kimberley Kolijn; Maria J. De Herdt; Berdine van der Steen; A. Marije Hoogland; Hein F.B.M. Sleddens; Leendert H.J. Looijenga; Geert J.L.H. van Leenders

doi:10.18632/oncotarget.8829

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MET expression during prostate cancer progression

Esther I. Verhoef _, Kimberley Kolijn, Maria J. De Herdt, Berdine van der Steen, A. Marije Hoogland, Hein F.B.M. Sleddens, Leendert H.J. Looijenga and Geert J.L.H. van Leenders

PDF | HTML | How to cite

Oncotarget. 2016; 7:31029-31036. https://doi.org/10.18632/oncotarget.8829

Metrics: PDF 1824 views | HTML 1973 views | ?

Abstract

Esther I. Verhoef1, Kimberley Kolijn1,*, Maria J. De Herdt2,*, Berdine van der Steen2, A. Marije Hoogland1, Hein F.B.M. Sleddens1, Leendert H.J. Looijenga1, Geert J.L.H. van Leenders1

1Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands

2Othorhinolaryngology and Head and Neck Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands

*These authors have contributed equally to this work

Correspondence to:

Esther I. Verhoef, e-mail: [email protected]

Keywords: MET, prostate cancer, progression, protein

Received: February 22, 2016 Accepted: March 31, 2016 Published: April 18, 2016

ABSTRACT

Tyrosine-kinase inhibitors of the hepatocyte growth factor receptor MET are under investigation for the treatment of hormone-refractory prostate cancer (HRPC) metastasis. Analysis of MET protein expression and genetic alterations might contribute to therapeutic stratification of prostate cancer patients. Our objective was to investigate MET on protein, DNA and RNA level in clinical prostate cancer at various stages of progression.

Expression of MET was analyzed in hormone-naive primary prostate cancers (N=481), lymph node (N=40) and bone (N=8) metastases, as well as HRPC (N=54) and bone metastases (N=15). MET protein expression was analyzed by immunohistochemistry (D1C2 C-terminal antibody). MET mRNA levels and MET DNA copy numbers were determined by in situ hybridization.

None of the hormone-naive primary prostate cancer or lymph node metastases demonstrated MET protein or mRNA expression. In contrast, MET protein was expressed in 12/52 (23%) evaluable HRPC resections. RNA in situ demonstrated cytoplasmic signals in 14/54 (26%) of the HRPC patients, and was associated with MET protein expression (p=0.025, χ²), in absence of MET amplification or polysomy. MET protein expression was present in 7/8 (88%) hormone-naive and 10/15 (67%) HRPC bone metastases, without association of HRPC (p=0.37; χ²), with MET polysomy in 8/13 (61%) evaluable cases.

In conclusion, MET was almost exclusively expressed in HRPC and prostate cancer bone metastasis, but was not related to MET amplification or polysomy. Evaluation of MET status could be relevant for therapeutic stratification of late stage prostate cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8829

Publication Alerts

Research Papers:

MET expression during prostate cancer progression

Abstract